Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
60 stopped studies mapped to Lung Non-Squamous Non-Small Cell Carcinoma and descendants · 95% state a reason
Over the 60 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for… | Phase 2 | terminated | Nov 13, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients… | Phase 1 | terminated | Jul 9, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung… | Phase 1 | terminated | Jun 16, 2020 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | Phase 1 / Phase 2 | withdrawn | Oct 4, 2022 | Intima Bioscience, Inc. | No recruitment | Enrollment / accrual |
| NCT03366766 | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable… | Phase 2 | terminated | Dec 8, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | slow accrual and lack of additional funding | Enrollment / accrual |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT04524689 | Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab…(CARMEN-LC05) | Phase 2 | terminated | Aug 24, 2020 | Sanofi | Sponsor decision, the decision is not related to any safety concern. | Safety / toxicity |
| NCT05317078 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin… | Phase 1 | terminated | Apr 7, 2022 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT04619433 | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects… | Phase 3 | terminated | Nov 6, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT05245071 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5…(CARMEN-LC06) | Phase 2 | terminated | Feb 17, 2022 | Sanofi | Sponsor decision, the decision is not related to any safety concern. | Safety / toxicity |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT06643117 | Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as…(Lotus) | Phase 3 | terminated | Oct 16, 2024 | Formycon AG | Formycon concluded that continuing the trial is no longer necessary for the development and… | Other (stated, no rule matched) |
| NCT04786964 | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line…(CONTERNO) | Phase 3 | terminated | Mar 8, 2021 | Checkpoint Therapeutics, Inc. | Regional political conflict | Other (stated, no rule matched) |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes… | Phase 1 / Phase 2 | terminated | Dec 13, 2017 | Janssen Research & Development, LLC | Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical… | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | Phase 2 | withdrawn | Jun 29, 2021 | University of British Columbia | Overestimated pool of eligible patients and the potential participants either declined… | Other (stated, no rule matched) |
| NCT05849246 | The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab… | Phase 2 | terminated | May 8, 2023 | Innovent Biologics (Suzhou) Co. Ltd. | strategy terminates development, the decision is not due to any safety-related issues | Safety / toxicity |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing… | Phase 2 | terminated | Jul 22, 2019 | National Cancer Institute (NCI) | Study was terminated due to slow accrual. | Enrollment / accrual |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT03190239 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced…(XQonc-007) | Phase 2 | withdrawn | Jun 16, 2017 | Xinqiao Hospital of Chongqing | abandon | Other (stated, no rule matched) |
| NCT03792503 | Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small… | Phase 4 | withdrawn | Jan 3, 2019 | Xinqiao Hospital of Chongqing | abandon | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT04971187 | Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant… | Phase 2 | terminated | Jul 21, 2021 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in… | Phase 3 | terminated | Jul 27, 2009 | SWOG Cancer Research Network | terminated at pre-planned futility analysis | Efficacy / futility |
| NCT04698681 | NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE… | — | terminated | Jan 7, 2021 | Calithera Biosciences, Inc | Lack of Clinical Benefit | Efficacy / futility |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | Phase 1 | terminated | Apr 27, 2021 | Innovent Biologics (Suzhou) Co. Ltd. | No signs of efficacy in solid tumors | Efficacy / futility |
| NCT04265534 | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in…(KEAPSAKE) | Phase 2 | terminated | Feb 11, 2020 | Calithera Biosciences, Inc | Lack of Clinical Benefit | Efficacy / futility |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | Phase 2 | terminated | Mar 26, 2019 | Helix BioPharma Corporation | Study was halted at this time due to other budgetary priorities. Completion of reporting has been… | COVID-19 / pandemic |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or… | Phase 2 | terminated | Feb 2, 2017 | Nasser Hanna, M.D. | Funder decision - lack of accrual | Enrollment / accrual |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer… | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by IRB on 3/28/22 | Other (stated, no rule matched) |
| NCT03319316 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non…(SOLUTION) | Phase 2 | withdrawn | Oct 24, 2017 | European Organisation for Research and Treatment of Cancer - EORTC | Interest withdrawn | Other (stated, no rule matched) |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV… | Phase 2 | terminated | Dec 3, 2015 | Henan Cancer Hospital | As there are so many clinical trials in progress and the number of patients enrolled limited. | Enrollment / accrual |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of… | Phase 3 | terminated | Nov 19, 2010 | Daiichi Sankyo | Sponsor decision due to the protocol-defined stopping boundary for futility was met based on the… | Efficacy / futility |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on… | Phase 2 | terminated | Sep 26, 2008 | Hoffmann-La Roche | The study was terminated due to the termination of the clinical development program. | Other (stated, no rule matched) |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC…(N3) | Phase 1 / Phase 2 | withdrawn | Dec 4, 2017 | Royal Marsden NHS Foundation Trust | Withdrawal of financial support from funder | Funding |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT02452463 | Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in… | Phase 2 | terminated | May 22, 2015 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV… | Phase 2 | terminated | May 9, 2014 | SWOG Cancer Research Network | science has moved forward and there is no intent to complete the study | Other (stated, no rule matched) |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung… | Early Phase 1 | terminated | Oct 16, 2012 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Phase 1 / Phase 2 | withdrawn | Jun 9, 2015 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT02891733 | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung…(NTS) | — | withdrawn | Sep 7, 2016 | Fondation Hôpital Saint-Joseph | The principal investigator decided to stop the study. | Investigator |
| NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With… | Phase 2 | terminated | Apr 17, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low enrollment | Enrollment / accrual |
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients… | Phase 2 | terminated | Aug 10, 2009 | National Cancer Institute (NCI) | The study was closed to accrual due to the end of the clinical development program with cixutumumab. | Enrollment / accrual |
| NCT02326285 | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in…(NeoIntercal) | Phase 2 / Phase 3 | terminated | Dec 29, 2014 | AIO-Studien-gGmbH | Due to low patient enrollment was stopped. Only one patient could be enrolled. 37 patients were… | Enrollment / accrual |
| NCT02121925 | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in…(ONC003) | — | terminated | Apr 24, 2014 | Myriad Genetic Laboratories, Inc. | Company decision to terminate | Sponsor / business decision |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | — | terminated | Mar 22, 2016 | Pathway Genomics | Patient accrual was slow due to exclusion of patients with prior cancers | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 8, 2026source: clinicaltrials